logo
Products
Technologies
Applications
Services
Resources
Selection Guides
About
Purified Anti-human CD14 Antibody
61D3
61D3 is an anti-human monoclonal antibody that targets the CD14 antigen. CD14 (sometimes referred to as myeloid cell-specific leucine-rich glycoprotein or LPS receptor) is a transmembrane protein that is located on the surface of cells such as macrophages. CD14 acts in critical cellular pathways, for example, the toll-like receptor signaling pathway, cell surface receptor signaling pathway and lipopolysaccharide-mediated signaling pathway. Moreover, in certain organisms, it promotes interleukin-8 secretion, is a positive regulator of tumor necrosis factor production and is a promoter of type I interferon production. From a research standpoint, it is of biological interest due to its association with essential macromolecules/ligands like LY96. CD14 is a very popular antibody target, with over 42000 publications in the last decade. CD14 is essential for immunology, cell biology and neuroscience research, often serving as a phenotypic marker for differentiating cell types in flow cytometric applications. This antibody was purified through affinity chromatography.
General packaging for catalog 10141000. Actual shipped packaging may vary.
General packaging for catalog 10141000. Actual shipped packaging may vary.
CatalogSize
Price
Quantity
10141000100 ug
Price
 
Physical properties

Molecular weightN/A
Solventwater
Antibody properties

Other namesLPS-Receptor
Clone61D3
Hostmouse
Reactivityhuman
ApplicationFlow Cytometry (FACS); ELISA; IHC; Western Blot
Storage, safety and handling

H-phraseH303, H313, H333
Hazard symbolXN
Intended useResearch Use Only (RUO)
R-phraseR20, R21, R22
StorageRefrigerated (2-8 °C); Minimize light exposure
Contact us

Telephone
Fax
Emailsales@aatbio.com
InternationalSee distributors
Bulk requestInquire
Custom sizeInquire
Technical SupportContact us
Request quotationRequest
Purchase orderSend to sales@aatbio.com
ShippingStandard overnight for United States, inquire for international
Page updated on November 4, 2025